| (Values in U.S. Thousands) | Mar, 2023 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Sep, 2021 |
| Sales | 266,000 | 299,000 | 307,000 | 299,000 | 284,000 |
| Sales Growth | -11.04% | -2.61% | +2.68% | +5.28% | -3.07% |
| Net Income | 47,000 | 59,000 | 4,000 | -107,000 | 47,000 |
| Net Income Growth | -20.34% | +1,375.00% | +103.74% | -327.66% | -12.96% |
Indivior Plc (INDV.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Fiscal Year End Date: 12/31